Phase II trial evaluates pembrolizumab combined with chemotherapy for improved outcomes in low-grade serous ovarian cancer, indicating potential therapeutic advancements.
Low-grade serous ovarian cancer (LGSOC) is a rare malignancy with limited responsiveness to chemotherapy, highlighting the urgent need for novel therapeutic strategies to improve treatment outcomes. Immune checkpoint inhibitors, such as pembrolizumab, have demonstrated efficacy in various cancers, including certain ovarian cancer subtypes, and could represent a promising treatment option for LGSOC.
No takes yet. Share an insight, caveat, or question.
Grabowski et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: